Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Japan on Alert over US MFN Drug Pricing Policy: Health Minister
Health Minister Kenichiro Ueno on June 19 voiced strong concerns that the US most favored nation (MFN) drug pricing policy could worsen Japan’s drug lag and drug loss problems, saying the government must address the issue with “a considerable sense…
To read the full story
REGULATORY
- Japan Approves Wegovy MASH Use, AstraZeneca’s Etcamah, Others
June 22, 2026
- Japan on Alert over US MFN Drug Pricing Policy: Health Minister
June 22, 2026
- Japan Restarts Deliberations on Routine Mumps Vaccination, Eyes FY2027 Rollout
June 22, 2026
- Japan Panel Backs Revaccination after Allogeneic Stem Cell Transplantation
June 22, 2026
- MHLW to Carefully Prepare Rollout of OTC-Like Drug Charge System
June 22, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…